Clinica Chimica Acta最新文献

{"title":"MicroRNA biosensors for cardiovascular disease detection","authors":"Asma Vafadar ,&nbsp;Sajad Alavimanesh ,&nbsp;Sepideh Babadi ,&nbsp;Vahid Hosseinpour ,&nbsp;Sajad Ehtiati ,&nbsp;Amir Savardashtaki","doi":"10.1016/j.cca.2025.120525","DOIUrl":"10.1016/j.cca.2025.120525","url":null,"abstract":"<div><div>Cardiovascular diseases (CVDs) remain one of the highest causes of death around the world. Early identification and quick intervention are vital for improving patient outcomes. MicroRNAs (miRNAs), small non-coding RNA molecules, have emerged as significant biomarkers for CVDs due to their involvement in various cellular activities, including cardiac hypertrophy, angiogenesis, and inflammation. Electrochemical biosensors offer a rapid, highly target-specific, cost-effective solution for detecting miRNA biomarkers in biological fluids. By utilizing nanomaterials and biorecognition elements, these sensors enable real-time observation of CVD progression and the patient’s response to treatment. This review investigates the potential applications of miRNA-based electrochemical biosensors for the prompt detection of CVDs. It magnifies the significance of miRNAs in the pathophysiology of cardiovascular disorders, such as myocardial infarction, heart failure, and atherosclerosis. Moreover, we emphasize the latest innovations in electrochemical biosensors to identify miRNA biomarkers in blood, serum, and various biological samples. Drawing upon recent developments and our experience in molecular diagnostics and biosensor applications, this review highlights the integration of nanomaterial-based electrochemical biosensors for detecting microRNAs associated with cardiovascular conditions. The literature reviewed in this article was gathered from databases including PubMed, Scopus, and Web of Science using keywords such as “microRNA,” “cardiovascular disease,” and “electrochemical biosensors.”</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"578 ","pages":"Article 120525"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exosomal cargoes as potential biomarkers for latent tuberculosis infection: a promising frontier in diagnosis?","authors":"Haorong Chen ,&nbsp;Sijing Liang ,&nbsp;Wenli Li ,&nbsp;Ting Cao ,&nbsp;Shujun Geng ,&nbsp;Jun Liu","doi":"10.1016/j.cca.2025.120523","DOIUrl":"10.1016/j.cca.2025.120523","url":null,"abstract":"<div><div>This article examines the potential of exosome analysis in diagnosing latent tuberculosis infection (LTBI). Tuberculosis (TB), caused by <em>Mycobacterium tuberculosis</em>, remains a significant public health challenge due to its high incidence worldwide. LTBI is a critical link in TB prevention and control but is also a major obstacle to achieving TB eradication. Current diagnostic methods, such as the tuberculin skin test and interferon-γ release assays, have limitations. Exosomes, small vesicles released by cells, contain DNA, RNA, proteins, and lipids that reflect the host cell’s pathological state and may serve as novel biomarkers for LTBI diagnosis. The article introduces exosome formation and extraction methods, explores the pathological mechanisms of mycobacterial vesicles and exosomes from infected hosts, and reviews research progress on exosomal DNA, non-coding RNA, proteins, and lipids as diagnostic markers for LTBI. Despite their potential, exosome research and application face challenges, including complex separation and purification processes, the dynamic nature of LTBI, and biomarker specificity. Future research will require multidisciplinary collaboration to develop efficient exosome-separation techniques and to further investigate the clinical value of these biomarkers, ultimately promoting the application of exosomes in LTBI diagnosis and contributing to global TB prevention and control efforts.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"578 ","pages":"Article 120523"},"PeriodicalIF":2.9,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144738529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three cases of false decrease interference of etamsylate on biochemical laboratory tests and correction methods","authors":"Hongming Wei ,&nbsp;Jei Feng ,&nbsp;Lin Zhu ,&nbsp;Yulin Wu ,&nbsp;Hui Ma ,&nbsp;Yanhong Gao","doi":"10.1016/j.cca.2025.120524","DOIUrl":"10.1016/j.cca.2025.120524","url":null,"abstract":"<div><h3>Background</h3><div>Etamsylate, a commonly used clinical hemostatic agent, may cause false decreases in biochemical test results through inhibition of enzymatic activity or interference with chromogenic reactions. However, insufficient research on its interference mechanisms and correction methods increases the risk of clinical misjudgment.</div></div><div><h3>Methods</h3><div>Serum samples were collected from three patients treated with etamsylate and analyzed using the Roche Cobas 8000 c701 automated biochemical analyzer. Samples were tested at undiluted (0-fold), 3-fold, 5-fold, and 10-fold dilution gradients to evaluate drug interference characteristics and the efficacy of dilution-based correction.</div></div><div><h3>Results</h3><div>Among the 46 routine biochemical assays evaluated, etamsylate exhibited significant negative interference on 12 parameters, including creatinine (CREA), albumin (ALB), and cholyglycine (CG). The interference diminished linearly with increasing dilution factors, demonstrating a dose-dependent recovery trend. CG demonstrated the most pronounced changes. No significant interference was observed for 12 other tests, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Following dilution, six parameters, including apolipoprotein A1 (APOA1), apolipoprotein A2 (APOA2), and apolipoprotein B (APOB), exhibited a paradoxical decrease in assay results, suggesting the presence of distinct interference mechanisms.</div></div><div><h3>Conclusion</h3><div>The dilution method can effectively correct the false decrease interference of etamsylate on biochemical detection. However, it is necessary to optimize the dilution factors to avoid loss of sensitivity. It is recommended that laboratories establish a drug interference database, standardize the gradient dilution process, and promote multi-disciplinary collaboration to optimize the detection system.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"578 ","pages":"Article 120524"},"PeriodicalIF":2.9,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rapid CRISPR/Cas12a-based assay for the detection of HIV-1 Clade C in infants","authors":"Anjli Gaur ,&nbsp;Harsh Bhakhri ,&nbsp;Nitesh Mishra ,&nbsp;Shaifali Sharma ,&nbsp;Tanu Bansal ,&nbsp;Mani Kalaivani ,&nbsp;Megha Brijwal ,&nbsp;Bimal Kumar Das ,&nbsp;Rakesh Lodha ,&nbsp;Subrata Sinha ,&nbsp;Kalpana Luthra","doi":"10.1016/j.cca.2025.120518","DOIUrl":"10.1016/j.cca.2025.120518","url":null,"abstract":"<div><h3>Background</h3><div>Early detection of HIV-1 infection is essential for initiating antiretroviral therapy (ART) to suppress viremia and prevent disease progression. Timely diagnosis, especially in infants, is critical as rapid antibody-based serology tests are ineffective due to the presence of maternal antibodies.</div></div><div><h3>Methods</h3><div>We developed a CRISPR/Cas12a-based HIV-1 detection assay by optimizing components for coupled isothermal preamplification using recombinase polymerase amplification (RPA). The assay targeted the conserved region in the pol gene specific to HIV-1 with the designed CRISPR RNA (crRNA). CRISPR/Cas12a-mediated cleavage of viral cDNA was visualized through the collateral cleavage of a single-stranded DNA-FAM-BQ reporter, enabling rapid and visually detectable outcomes. The performance of the assay was evaluated using plasma from 41 HIV-1 Clade C (HIV-1C) seropositive individuals, including 28 HIV-1C infected infant samples, HIV-1 Indian Clade C and Clade B genome plasmids, viral disease control DNA/RNA samples (Influenza, RSV, Parvovirus, HPIV, CMV, and HBV), and 31 healthy donor plasma samples. Sensitivity and specificity were assessed, and detection was performed using fluorescence, visual readout, and lateral flow dipsticks.</div></div><div><h3>Results</h3><div>The CRISPR/Cas12a-based HIV-1 Clade C detection assay achieved a sensitivity of 96 % and a specificity of 92.65 %. The assay successfully provided results through both fluorescence and visual readouts and was compatible with lateral flow dipstick formats, facilitating easy and rapid detection.</div></div><div><h3>Conclusions</h3><div>The developed CRISPR/Cas12a-based HIV-1C detection assay demonstrates high sensitivity and specificity for Clade C, indicating its potential as a robust point-of-care molecular diagnostic tool for HIV-1C. Additionally, it may serve as a rapid nucleic acid test alternative for detecting mother-to-child transmission of HIV-1C in infants under two years of age, where traditional antibody-based tests are ineffective. This assay holds promise for improving early HIV-1 diagnosis and timely initiation of ART, ultimately contributing to better disease management and outcomes.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"578 ","pages":"Article 120518"},"PeriodicalIF":2.9,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electrochemical sensors for diagnosis and monitoring of acute lymphoblastic leukaemia","authors":"Joshua Lehr,&nbsp;Ifrah Sattar,&nbsp;Mark Mc Auley","doi":"10.1016/j.cca.2025.120522","DOIUrl":"10.1016/j.cca.2025.120522","url":null,"abstract":"<div><div>Acute Lymphoblastic Leukaemia (ALL) is a deadly form of blood cancer which occurs predominantly in children. It represents one of the most prevalent paediatric cancers. Both the diagnosis and monitoring of ALL presents clinicians with significant challenges. Diagnosis and monitoring of such paediatric conditions can be challenging due to the limitations in the patient’s ability to communicate symptoms clearly. Early diagnosis is vital for improving the chances of positive outcomes for patients. Similarly rapid, real-time prognostics allows clinicians to adjust treatment in a timely manner. This enhances survival prospects by both early diagnosis and monitoring of relapse and also helps to avoid damage caused by unnecessary excessive and harsh treatment when the patient is in remission. The latter is especially pertinent to young and vulnerable patients. Unfortunately, current diagnostic and prognostic tests for ALL are cumbersome, slow, and require specialised facilities and trained staff. As a consequence, they are neither rapid − nor can they be widely applied. Electrochemical biosensors have the potential to underpin rapid, self-administered, high-frequency, cost-effective and point-of-care monitoring of relevant (protein and nucleic acid) biomarkers. The development of such technologies has the potential to overcome the shortcomings of current ALL diagnostic and prognostic methods. Herein, we review the literature in electrochemical biosensors for ALL diagnostics and prognostics, identifying trends and suggesting promising avenues for future work.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"578 ","pages":"Article 120522"},"PeriodicalIF":2.9,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of next-generation sequencing in the detection of antimicrobial resistance","authors":"Haojun Wang ,&nbsp;Chuan Ye ,&nbsp;Hongyan Jiang ,&nbsp;Rao Song","doi":"10.1016/j.cca.2025.120520","DOIUrl":"10.1016/j.cca.2025.120520","url":null,"abstract":"<div><div>Antimicrobial resistance (AMR) is increasing on a global scale, necessitating the development of diagnostic tools that are more accurate, comprehensive, and rapid. Traditional phenotypic methods, such as culture-based antimicrobial susceptibility testing, are constrained by low throughput and limited applicability to polymicrobial or non-culturable pathogens. In contrast, Next-Generation Sequencing (NGS) technologies have transformed resistance detection by enabling high-resolution genotyping. This review provides a comprehensive overview of major sequencing strategies and evaluates their clinical applications for detecting drug resistance across diverse pathogens, while critically examining the advantages and limitations of each platform. Despite ongoing challenges including high cost, technical complexity, and imperfect genotype-phenotype correlations, recent advances in artificial intelligence (AI)-assisted analysis, resistance gene databases, and portable sequencing platforms are progressively bridging the gap between research and clinical implementation. NGS-based diagnostics are poised to become indispensable tools for precision antimicrobial therapy and global AMR surveillance.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"578 ","pages":"Article 120520"},"PeriodicalIF":2.9,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144738528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ensemble learning-driven hybrid prediction model for improved prenatal down’s syndrome screening: a comparative study with laboratory-based median equations","authors":"Liping Hu ,&nbsp;Minglin Xu ,&nbsp;Yuqin Li ,&nbsp;Xiaoshan Wu ,&nbsp;Zhimei Zhang ,&nbsp;Min Dai ,&nbsp;Huan Chen ,&nbsp;Guolin Hong ,&nbsp;Yingting Zhuang","doi":"10.1016/j.cca.2025.120519","DOIUrl":"10.1016/j.cca.2025.120519","url":null,"abstract":"<div><h3>Objective</h3><div>This study developed and validated a hybrid prediction model (HyPred) for prenatal Down’s syndrome (DS) screening using ensemble learning（EL）-driven, including extreme gradient boosting, balanced random forest, and gradient boosting machine. Its performance was compared with laboratory-based median equations.</div></div><div><h3>Methods</h3><div>A retrospective analysis was conducted using 8,363 first-trimester samples (Nov 2019–Aug 2022) for training and 1,943 samples (Sep 2022–Jul 2023) for validation. HyPred was developed in R and compared with a laboratory-based median equation in terms of sensitivity, specificity, and other metrics.</div></div><div><h3>Results</h3><div>The lab-based median equation improved screening over the default equation. In the validation set, the EL model showed superior performance with higher accuracy, robustness, and adaptability. HyPred achieved an AUC of 0.97, surpassing the median equation in key metrics.</div></div><div><h3>Conclusion</h3><div>The EL model offers improved accuracy and robustness for prenatal DS screening. Despite higher computational demands, modern tools facilitate its optimization, supporting precision medicine through more customized screening.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"578 ","pages":"Article 120519"},"PeriodicalIF":2.9,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integration of coagulation parameters Enhances deep Learning-Based survival prediction in High-Grade serous ovarian Cancer: A comprehensive prognostic model","authors":"Pei Wang ,&nbsp;Xi Zhang ,&nbsp;Jing Shi ,&nbsp;Hongyan Meng ,&nbsp;Jie Wang ,&nbsp;Xiaoyan Wang ,&nbsp;Chunyan Wang ,&nbsp;Xiaojuan Wang","doi":"10.1016/j.cca.2025.120512","DOIUrl":"10.1016/j.cca.2025.120512","url":null,"abstract":"<div><h3>Background</h3><div>High-grade serous ovarian cancer (HGSOC) remains a leading cause of gynecologic cancer mortality, with heterogeneous clinical outcomes necessitating improved prognostic models. This study aimed to develop and validate a comprehensive survival prediction model integrating traditional clinicopathological factors with novel molecular and coagulation parameters.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 216 HGSOC patients treated between 2012 and 2017. A comprehensive machine learning framework incorporating 88 algorithms was developed to predict survival outcomes, integrating conventional prognostic factors with coagulation parameters, particularly D-dimer levels. Model performance was evaluated using time-dependent AUC, concordance index, and calibration curves. External validation was performed using an independent cohort of 108 patients from three institutions.</div></div><div><h3>Results</h3><div>The machine learning model demonstrated excellent discriminative capability (AUC 0.771, 95% CI 0.709–0.832), with improving predictive accuracy from 1-year to 5-year follow-up. Multivariate analysis identified five independent prognostic factors: p53 expression, lymphadenectomy, TNM stage, hypercoagulability, and Ki67 expression. The model showed robust performance in external validation.</div></div><div><h3>Conclusions</h3><div>Our novel machine learning-based survival prediction model demonstrates superior prognostic accuracy and temporal stability compared to conventional approaches. The integration of coagulation parameters provides new insights into disease progression. This model could facilitate personalized treatment decisions in clinical practice, though further prospective validation is warranted.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"578 ","pages":"Article 120512"},"PeriodicalIF":2.9,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid biopsy in neurodegenerative disease: A minimally invasive approach for early diagnosis","authors":"Saranya Udayakumar ,&nbsp;Agnishwar Girigoswami ,&nbsp;Koyeli Girigoswami","doi":"10.1016/j.cca.2025.120517","DOIUrl":"10.1016/j.cca.2025.120517","url":null,"abstract":"<div><div>Neurodegenerative diseases are difficult to diagnose due to their insidious nature and a lack of accurate early detection methods. Using biofluids such as saliva, blood, urine, tears, and cerebrospinal fluids, liquid biopsy has become a potential less invasive method for disease diagnosis. The clinical significance of liquid biopsy is studied in this review, which also highlights the important biomarkers, less invasive sample types, and multi-omic approaches such as proteomics, genomics, metabolomics, and transcriptomics. Furthermore, new developments that are being explored for their potential to improve disease monitoring and diagnostic advances include spectroscopic techniques, nanobiosensors, molecular biology-based tools, imaging techniques, and AI. Although biomarkers have a potential source, they face significant challenges such as specificity, standardization, and clinical validation. Future advancements in AI and multi-omics approaches may enhance the use of liquid biopsy. Early detection and personalized therapies are possible with this technology, which would ultimately improve patient outcomes in disease management.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"578 ","pages":"Article 120517"},"PeriodicalIF":2.9,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144722783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of an intelligent automated workflow for accurate platelet counting in hematology laboratory","authors":"A. Giovannelli ,&nbsp;M. Pieri ,&nbsp;F.G. Viola ,&nbsp;E. Nicolai ,&nbsp;M. Minieri ,&nbsp;F. Tomassetti ,&nbsp;M. Pelagalli ,&nbsp;S. Velocci ,&nbsp;M.A.I. Consalvo ,&nbsp;S. Gargiulo ,&nbsp;G. Colafranceschi ,&nbsp;R. Palmieri ,&nbsp;F. Buccisano ,&nbsp;S. Bernardini","doi":"10.1016/j.cca.2025.120514","DOIUrl":"10.1016/j.cca.2025.120514","url":null,"abstract":"<div><h3>Background</h3><div>Platelet (PLT) enumeration is essential for diagnosing hematological and coagulative disorders, but traditional methods face cost and training challenges. An intelligent PLT counting workflow was developed to automatically provide accurate PLT values, improving efficiency and costs. This study aims to validate the performance of this intelligent workflow, focusing on accuracy and efficiency.</div></div><div><h3>Methods</h3><div>A total of 1,208 samples (909 randomly selected and 299 abnormal samples exhibiting suspected PLT interference) from Tor Vergata University Hospital were analyzed using the Mindray BC-6800Plus analyzer, employing both impedance (PLT-I) and fluorescent (PLT-O) techniques. Blood smears were prepared using the SC-120 slide maker and examined by the MC-80 morphology analyzer (PLT-M). Abnormal samples were also analyzed with CD41/CD61 immuno-platelet (immunoPLT) testing.</div></div><div><h3>Results</h3><div>Among 299 abnormal samples, 153 were assessed by PLT-I, showing a strong correlation with immunoPLT (R² = 0.943). For 49 samples, PLT-O showed a high correlation (R² = 0.989). The remaining samples (PLT-O &lt; 100 x 10⁹/L) were verified by morphology (PLT-M), with 95 confirmed (R² = 0.975). Only 2 samples required manual review due to PLT-M exceeding the PLT-O tolerance range. Overall, 1205 samples passed the automated workflow, with 234 needing PLT-O retesting, 161 requiring microscopy, and 3 needing manual review.</div></div><div><h3>Conclusion</h3><div>The intelligent PLT workflow accurately processed over 99% of samples, minimizing the need for fluorescent counting and blood smear reviews. It enhances laboratory efficiency, reduces manual intervention, and lowers reagent costs, supporting greater automation.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"578 ","pages":"Article 120514"},"PeriodicalIF":2.9,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144723621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}